Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Etoposide. Found 11 abstracts

Tammaro M, Liao SR, Beeharry N, Yan H. DNA double-strand breaks with 5 ' adducts are efficiently channeled to the DNA2-mediated resection pathway. Nucleic acids research. 2016 Jan;44(1):221-31.   PMCID: PMC4705695
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Langer CJ. The global role of irinotecan in the treatment of lung cancer: 2003 update. Oncology (Huntingt). 2003 Jul;17(7 Suppl 7):30-40.
Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B, Rivers P, Vonderheide RH, Liebowitz DN, Porter DL, June CH. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood. 2003 Sep 15;102(6):2004-13.
Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Semin Oncol. 2002 Feb;29(1 Suppl 1):20-31.
Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, Johnson DH. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. Journal of the National Cancer Institute. 2002 Feb 06;94(3):173-81.
Chen ZS, Aoki S, Komatsu M, Ueda K, Sumizawa T, Furukawa T, Okumura H, Ren XQ, Belinsky MG, Lee K, Kruh GD, Kobayashi M, Akiyama S. Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. International journal of cancer. 2001 Jul;93(1):107-13.
Kao GD, McKenna WG, Yen TJ. Detection of repair activity during the DNA damage-induced G2 delay in human cancer cells. Oncogene. 2001 Jun 14;20(27):3486-96.
Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am. 2001 Jun;15(3):525-45.
Movsas B, Scott C, Sause W, Byhardt R, Komaki R, Cox J, Johnson D, Lawton C, Dar AR, Wasserman T, Roach M, Lee JS, Andras E. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys. 1999 Dec;45(5):1143-9.
Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs. 1999 Jan;58 Suppl 3:43-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Etoposide

Etoposide Human Antineoplastic Combined Chemotherapy Protocols drug therapy therapeutic use administration & dosage Female Cisplatin genetics drug effects Lung Neoplasms Non-US Gov't Support Survival Analysis US Gov't Support-PHS Non-Small-Cell Lung Carcinoma Deoxycytidine Ovarian Neoplasms Phytogenic Antineoplastic Agents metabolism Treatment Outcome Male Aged Paclitaxel toxicity Doxorubicin Enzyme Inhibitors Combined Modality Therapy Phase II Clinical Trials pharmacology adverse effects Camptothecin Multicenter Studies 80 and over Aged Adjuvant Radiotherapy radiotherapy DNA Repair Clinical Trials Drug Administration Schedule Carboplatin Vindesine Adenocarcinoma Adjuvant Chemotherapy analogs & derivatives Antineoplastic Agents Phase III Clinical Trials Adult Neoplasm Staging EC 1-17-4 (Ribonucleotide Reductases) Microtubules Comparative Study Biological Transport 103882-84-4 (gemcitabine) tu [Therapeutic Cell Survival Colchicine analogs & Double-Stranded DNA Breaks effects Retrospective Studies Antineoplastic Antimetabolites Random Allocation ad [Administration & Dosage] Adolescent Recombinant Proteins Single-Stranded DNA Neoplasm Drug Resistance Cultured Tumor Cells 7689-03-4 (Camptothecin) Centromere North America Dexamethasone Ribonucleotide Reductases derivatives United States Cytarabine T-Lymphocytes Apoptosis radiation effects Neoplasm DNA Phytogenic) 0 (Antineoplastic Agents immunology Lymphocytosis Flow Cytometry CD34 Antigens bcl-2 Genes Cell Cycle Topotecan 0 (Antineoplastic Combined Chemotherapy Protocols) Small Cell Carcinoma Hela Cells 0 (Taxoids) Quality of Life physiology Multiple Drug Resistance Squamous Cell Carcinoma Carmustine Neoplasm Proteins Non-Histone Chromosomal Proteins Gene Expression Regulation Age Factors 33419-42-0 (Etoposide) Middle Age Middle Aged Phase I Clinical Trials Disease Progression Small Interfering RNA Antisense Oligodeoxyribonucleotides Remission Induction aa [Analogs & Derivatives] Hydrocortisone Local Neoplasm Recurrence pathology transplantation P-Glycoprotein Type II DNA Topoisomerases Gamma Rays Aging use Kinetics Hematopoietic Stem Cell Transplantation ai [Antagonists & Inhibitors] Taxoids Karnofsky Performance Status Bromodeoxyuridine 951-77-9 (Deoxycytidine) Proto-Oncogene Proteins c-bcl-2 Prostatic Neoplasms Adenosine Triphosphate Follow-Up Studies G2 Phase Palliative Care therapy KB Cells Prospective Studies Antineoplastic) 0 (Antimetabolites chemistry pharmacokinetics Vincristine Cell Membrane Tubulin Signal Transduction 0 (Antineoplastic Agents) Hematopoietic Stem Cells Marine Toxins Type I DNA Topoisomerases Recurrence 15663-27-1 (Cisplatin) Survival Rate 100286-90-6 (irinotecan) antagonists & inhibitors
Last updated on Friday, August 07, 2020